Friedreich's ataxia (FRDA) is a
neurodegenerative disease caused by reduced expression of the
protein frataxin.
Frataxin is thought to play a role in
iron-
sulfur cluster biogenesis and
heme synthesis. In this study, we used erythroid progenitor stem cells obtained from FRDA patients and healthy donors to investigate the putative role, if any, of
frataxin deficiency in
heme synthesis. We used electrochemiluminescence and qRT-PCR for
frataxin protein and
mRNA quantification. We used atomic absorption spectrophotometry for
iron levels and a photometric assay for
hemoglobin levels.
Protoporphyrin IX and
Ferrochelatase were analyzed using auto-fluorescence. An "IronChip" microarray analysis followed by a
protein-
protein interaction analysis was performed. FRDA patient cells showed no significant changes in
iron levels,
hemoglobin synthesis,
protoporphyrin IX levels, and
ferrochelatase activity. Microarray analysis presented 11 genes that were significantly changed in all patients compared to controls. The genes are especially involved in oxidative stress,
iron homeostasis and angiogenesis. The mystery about the involvement of
frataxin on
iron metabolism raises the question why
frataxin deficiency in primary FRDA cells did not lead to changes in biochemical parameters of
heme synthesis. It seems that alternative pathways can circumvent the impact of
frataxin deficiency on
heme synthesis. We show for the first time in primary FRDA patient cells that reduced
frataxin levels are still sufficient for
heme synthesis and possibly other mechanisms can overcome reduced
frataxin levels in this process. Our data strongly support the fact that so far no
anemia in FRDA patients was reported.